NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only

NSABP Foundation, Inc.

General NSABP Information
  Financial Conflicts of
     Interest Policy
  Coalition Comment:
  IOM Report Group Comment
  Contact the NSABP
  Pathology Section
  Future Meetings
  NSABP Newsletters
  Media Info on STAR

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-51
  Protocol B-52
  Protocol B-53/S1207
  Protocol B-55/BIG 6-13

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR
  Protocol P-5

Scientific Publications

Related Web Sites

Medical Search Engines

To report problems, ask
questions or make comments,
please send e-mail to:

NSABP Clinical Trials Overview

Protocol B-34
A Clinical Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy

Specific Aims
The primary aim of this phase III trial is to determine whether clodronate administered for 3 years either alone or in addition to adjuvant chemotherapy and/or hormonal therapy, in patients with early-stage breast cancer will improve disease-free survival. Secondary aims include determining whether clodronate will reduce the incidence of skeletal metastases, improve overall survival, improve relapse-free survival, reduce the incidence of non-skeletal metastases, and reduce the incidence of skeletal morbidity (skeletal fractures, hypercalcemia, skeletal pain, need for radiation therapy, spinal cord compression). Also to investigate the relevance of serum markers of bone turnover as a prognostic factor for the development of bone metastasis.